IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 1157 
Small font sizeDefault font sizeIncrease font size
Navigate Here
  Search
 
  
Resource Links
   Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
   Article in PDF (428 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)

 
In This Article
   References
   Article Figures
   Article Tables

 Article Access Statistics
    Viewed1176    
    Printed43    
    Emailed0    
    PDF Downloaded57    
    Comments [Add]    

Recommend this journal

 


 
 Table of Contents    
AUTHORS REPLY
Year : 2014  |  Volume : 46  |  Issue : 4  |  Page : 460-462
 

Author's Reply


1 Department of Medical Statistics and Epidemiology, Hamad Medical Corporation and, Departments of Public Health and Medical Education, Weill Cornell Medical College, Doha, Qatar
2 Department of Chemistry, Faculty of Arts and Science, Yildiz Technical University, Istanbul, Turkey
3 Clinical Pharmacy, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar
4 Diabetes and Health Education, Qatar Diabetic Association, and Qatar Foundation, Doha, Qatar

Date of Web Publication4-Jul-2014

Correspondence Address:
Abdulbari Bener
Department of Medical Statistics and Epidemiology, Hamad Medical Corporation and, Departments of Public Health and Medical Education, Weill Cornell Medical College, Doha
Qatar
Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions



How to cite this article:
Bener A, Dogan M, Barakat L, Al-Hamaq AO. Author's Reply. Indian J Pharmacol 2014;46:460-2

How to cite this URL:
Bener A, Dogan M, Barakat L, Al-Hamaq AO. Author's Reply. Indian J Pharmacol [serial online] 2014 [cited 2021 Dec 4];46:460-2. Available from: https://www.ijp-online.com/text.asp?2014/46/4/460/135971


Madam,

We would like to thank reader for his/her valuabale comments. Meanwhile, I would like to clarify and reply to the reader point-by-point as given below:

  1. This study is a cohort observational population-based study conducted at Hamad Medical Hospital and PHC Centre. [1] A total of 1,542 consecutive diabetes patients who were diagnosed with dyslipidemia and prescribed any of the indicated statins between January 2007 and September 2013 were included in the study. Since the study is based on cohort time interval and subjects who met and satisfied inclusion and exclusion criteria, there is no need for the sample size
  2. We do agree with the reader that there are typographical errors in the Results section. The third paragraph should read as: "Atorvastatin reduced LDL-C the most at a dose of 40 mg (15.9%) and atorvastatin reduced LDL-C the most at a dose of 20 mg (21.2%)," which is very clear and correct, as mentioned in [Table 1] of the published article
  3. As can be observed from the title of [Figure 1]b stated as, "Number of patients with no microalbuminuria at baseline but developed it after 2 years". Meanwhile, in the Results section the content and term has been used correctly; therefore, it is very obvious that the footnote of the graph incorrectly mentions microalbuminia instead of microalbuminuria. In fact, this typographical errors ocurred while using Excel Computer Software for graphical purposes
  4. It is true that we have solely mentioned the acquisition cost of rosuvastatin when compared to atorvastatin, which was available. We agree with the reader that a cost-effective analysis with the calculation of the incremental cost effectiveness ratio would have been much more appropriate and insightful; however, it was not main objective of this study.
Table 1: Comparison of the effi cacy of various statins in different doses (10, 20, and 40 mg)

Click here to view
Figure 1: (a) Rosuvastatin versus other statins, (b) Comparison of patients with pre- and posttreatment microalbuminuria at the end of 2 years

Click here to view


 
  References Top

1.Bener A, Dogan M, Barakat L, Al-Hamaq AO. Comparison of efficacy, safety, and cost-effectiveness of various statins in dyslipidemic diabetic patients. Indian J Pharmacol 2014;46:88-93.  Back to cited text no. 1
[PUBMED]  Medknow Journal  


    Figures

  [Figure 1]
 
 
    Tables

  [Table 1]



 

Top
Print this article  Email this article
 

    

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Wolters Kluwer - Medknow